Progress, documented.
Updates from Network Immunology across science, development, intellectual property, and company milestones.
Latest
January 2026
AbstimX™ enters veterinary clinical study
Network Immunology has initiated a study evaluating AbstimX™ in dogs with atopic dermatitis, conducted independently at an academic veterinary dermatology centre. Dogs naturally develop allergic conditions that share features with human disease, and the study is expected to provide information on safety, immune response and clinical effect.
June 2025
Japanese patent granted for AbstimX™
Network Immunology has been granted a Japanese patent covering AbstimX™. With grants now in place in the United States, China and Japan, the platform is protected in three of the four largest pharmaceutical markets. Applications remain pending in additional jurisdictions.
December 2024
China grants patent for AbstimX™
Network Immunology has been granted a Chinese patent covering AbstimX™, extending protection of the platform into one of the world's largest pharmaceutical markets.
September 2024
United States patent granted for AbstimX™
The United States Patent and Trademark Office has granted Network Immunology patent US 12,090,202, covering AbstimX™ for the treatment and prevention of allergic disease. The patent includes a composition claim over the two-component combination and remains in force to December 2041.
If we publish it, something happened.
Patent grants. Peer-reviewed publications. Study milestones. Formal appointments. Financing announcements. Partnerships and collaborations. Major company updates.
No filler posts. No publishing for the sake of activity.
Stay close to the work.
Receive occasional updates from Network Immunology.